Seasoned growth-stage investor and operator focused on consumer and fintech sectors, with experience across investment sourcing, portfolio operations and strategic M&A. Jeremy Edelstein brings a background in venture capital and operational leadership, often serving on growth-company boards to drive customer acquisition and revenue scaling. Known for structuring growth equity and minority-stake deals, and for hands-on support of go-to-market and product strategy, he engages with founders on fundraising and exit planning. Active in US venture networks and frequently advising on capital strategy and business development.
Seasoned growth-stage investor and operator focused on consumer and fintech sectors, with experience across investment sourcing, portfolio operations and strategic M&A. Jeremy Edelstein brings a background in venture capital and operational leadership, often serving on growth-company boards to drive customer acquisition and revenue scaling. Known for structuring growth equity and minority-stake deals, and for hands-on support of go-to-market and product strategy, he engages with founders on fundraising and exit planning. Active in US venture networks and frequently advising on capital strategy and business development.
Growth-stage investor focused on consumer and fintech businesses, blending capital provision with active operational partnership to accelerate customer acquisition and revenue scaling. Prioritizes minority and structured growth-equity positions that preserve founder alignment while providing governance and strategic support. Underwrites opportunities using unit economics, go-to-market traction, and product-led growth signals, favoring repeatable revenue models and clear paths to profitable scale. Employs hands-on portfolio playbook—board engagement, GTM execution, and M&A readiness—with a multi-year horizon, disciplined capital pacing, and a bias toward follow-on reserves to protect upside.
Growth-stage investor focused on consumer and fintech businesses, blending capital provision with active operational partnership to accelerate customer acquisition and revenue scaling. Prioritizes minority and structured growth-equity positions that preserve founder alignment while providing governance and strategic support. Underwrites opportunities using unit economics, go-to-market traction, and product-led growth signals, favoring repeatable revenue models and clear paths to profitable scale. Employs hands-on portfolio playbook—board engagement, GTM execution, and M&A readiness—with a multi-year horizon, disciplined capital pacing, and a bias toward follow-on reserves to protect upside.
| Trades 149 | Longs Won 98/149 65% | Profit Factor 6.21 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $4.81M |
| Average Win $2.89M | Best Trade (Jun 29) $41.94M | Sharpe Ratio -8.5 |
| Average Loss -$894,583.67 | Worst Trade (Mar 31) -$6.37M | Z-Score 0.08 (6.01%) |
| Commissions $0 | Avg. Trade Length 11m 1w 3d | Expectancy $1.45M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.38% |
| Consecutive Losing Trades | 472 | 425 | 378 | 331 | 283 | 236 | 189 | 142 | 94 | 47 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
ABUS Arbutus Biopharma Corporation | 2.5M | $8.02M | $11.68M | - | $3.66M | 45.6% | +1.965% |
AMRX Amneal Pharmaceuticals Inc. | 1.3M | $10.84M | $23.59M | - | $12.75M | 117.64% | +5.096% |
AZLUD Azul S.A. Sponsored ADR each representing 3 preferred shares | 1.68M | $15.14M | $15.14M | - | - | - | 0.0 |
CCOI Cogent Communications Holdings, Inc. | 250,000 | $5.39M | $2.83M | - | -$2.56M | -47.54% | +9.275% |
CRC California Resources Corp | 175,000 | $9.25M | $9.33M | - | $77,000 | 0.83% | +1.062% |
DHC Diversified Healthcare Trust | 4.08M | $12.2M | $34.15M | - | $21.95M | 179.96% | +0.119% |
MH McGraw Hill, Inc. | 2.45M | $32.6M | $32.09M | - | -$500,330.53 | -1.53% | -3.464% |
NEE NextEra Energy, Inc. | 335,000 | $24.08M | $28.87M | - | $4.79M | 19.89% | +0.209% |
| NIQ NIQ | 2.9M | $40.56M | $47.88M | - | $7.33M | 18.06% | 0.0 |
NXPI NXP Semiconductors N.V. | 90,000 | $20.24M | $21.12M | - | $881,400.9 | 4.35% | +1.207% |
OXY Occidental Petroleum Corporation | 250,000 | $12.14M | $14.59M | - | $2.45M | 20.16% | +1.144% |
PRVA Privia Health Group, Inc. | 1.58M | $34.26M | $34.87M | - | $609,946.78 | 1.78% | +1.103% |
ROIV Roivant Sciences Ltd | 2M | $21.87M | $72.4M | - | $50.53M | 231.04% | -0.221% |
SEAT Vivid Seats Inc. | 500,000 | $2.96M | $3.59M | - | $635,000 | 21.49% | +0.279% |
UNH UnitedHealth Group Incorporated | 65,000 | $27.02M | $26.11M | - | -$903,499.35 | -3.34% | +0.669% |
VG Venture Global Inc. | 1.75M | $19.48M | $24.48M | - | $5M | 25.7% | +3.323% |
VKTX Viking Therapeutics Inc. | 600,000 | $16.73M | $19.91M | - | $3.18M | 19.01% | +0.759% |